Product information and disease description
Place of product in therapy
50 evidence topics · 39 sources
Zanzalintinib (XL092)
Metastatic colorectal cancer
- Manufacturer
- Exelixis
- Regulatory submission
- NDA submitted December 2025
- Launch
- Not announced
- Last updated